Margarida Azevedo, MSc,  —

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Articles by Margarida Azevedo

VA Adds Radicava to its National Formulary for ALS Patients

The U.S. Department of Veterans Affairs (VA) has added Radicava (edaravone) to its national formulary (VANF), making it possible for veterans with amyotrophic lateral sclerosis (ALS) to access treatment within the VA’s healthcare system, according to Mitsubishi Tanabe Pharma America (MTPA). The VANF is a list of drugs and…

Muscular Dystrophy Association Awards $3.5M in New Research Grants

The Muscular Dystrophy Association (MDA) is financing 13 new research programs aimed at developing treatments for amyotrophic lateral sclerosis (ALS) and other life-threatening diseases. Toward that goal, the organization recently announced it would distribute $3.5 million in new development grants. For the summer round of grants, 244 applicants submitted…